Scholarlink

Background <p>People who inject drugs (PWID) face a substantial risk of hepatitis C virus (HCV) infection, often in the context of multiple injecting partnerships. The disclosure of HCV status to injecting partners holds significant implications for prevention and care among PWID.</p> Methods <p>We used cross-sectional dyadic survey data (collected from both members of injecting partnerships) to estimate the prevalence of HCV-status disclosure between PWID and their injecting partners, overall and by partnership HCV infection status.</p> Results <p>Across the two study sites (San Francisco and Montreal), 91% of participants self-reported receiving an HCV test, resulting in 162 individuals and 131 partnerships. A majority (57%) self-reported being HCV positive. HCV status disclosure was prevalent overall (79%) and was most common (41%) with partnerships where both partners’ status was positive (+ / +) but less common (17%) when one partner was positive ( ±) and when neither partner was positive (-/-) (32%); no disclosure was more common when both partners were negative (-/-) (50%).</p> Conclusions <p>Overall, our study demonstrated a high prevalence of HCV testing and subsequent disclosure of HCV status within injecting partnerships. This presents an opportunity to leverage these relationships for treatment linkage and prevention messaging.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Getting to full disclosure: HCV testing and status disclosure behaviors among PWID and their injecting partners

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月8日

查看全文
  • Maia Scarpetta,
  • Rachel Kanner,
  • Neia Prata Menezes,
  • Claire C. McDonell,
  • Julie Bruneau,
  • Kimberly Page,
  • Meghan D. Morris

摘要

Background

People who inject drugs (PWID) face a substantial risk of hepatitis C virus (HCV) infection, often in the context of multiple injecting partnerships. The disclosure of HCV status to injecting partners holds significant implications for prevention and care among PWID.

Methods

We used cross-sectional dyadic survey data (collected from both members of injecting partnerships) to estimate the prevalence of HCV-status disclosure between PWID and their injecting partners, overall and by partnership HCV infection status.

Results

Across the two study sites (San Francisco and Montreal), 91% of participants self-reported receiving an HCV test, resulting in 162 individuals and 131 partnerships. A majority (57%) self-reported being HCV positive. HCV status disclosure was prevalent overall (79%) and was most common (41%) with partnerships where both partners’ status was positive (+ / +) but less common (17%) when one partner was positive ( ±) and when neither partner was positive (-/-) (32%); no disclosure was more common when both partners were negative (-/-) (50%).

Conclusions

Overall, our study demonstrated a high prevalence of HCV testing and subsequent disclosure of HCV status within injecting partnerships. This presents an opportunity to leverage these relationships for treatment linkage and prevention messaging.